BioPharma Resources

Company · LLY

Eli Lilly

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Eli Lilly and Company; Loxo Oncology, Inc..

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

91

40 still marketed

Novel approvals

44

Approvals since 2021

58

Originals and new uses

Phase 3 trials

559

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (32)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • BrenipatideLY3537031Phase 313 trials

    Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • MazdutideLY3305677Phase 35 trials

    Eli Lilly · Type 2 Diabetes, Obesity, Overweight

  • MibavademabREGN4461Phase 35 trials

    Regeneron · Generalized Lipodystrophy, Functional Hypothalamic Amenorrhea, FHA

  • TersolisibLY4064809, STX-478Phase 33 trials

    Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • LepodisiranLY3819469Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

  • VepugratinibLY3866288Phase 32 trials

    Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3

  • RemternetugLY3372993Phase 31 trial

    Eli Lilly · Alzheimer's Disease

  • MORF-057zotemtegrast, LY4268989Phase 24 trials

    Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)

  • LY4065967Phase 23 trials

    Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee

  • MacupatideLY3532226Phase 23 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • BimagrumabLY3985863, BYM338Phase 22 trials

    Eli Lilly · Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction

  • EltrekibartLY3041658Phase 22 trials

    Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa

  • LY188011Phase 22 trials

    Eli Lilly · Neoplasms, Child, Adolescent

  • LY3549492Phase 22 trials

    Eli Lilly · Obesity, Overweight

  • LY4005130Phase 22 trials

    Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)

  • LY4395089Phase 22 trials

    Eli Lilly · Crohn Disease, Colitis, Ulcerative

  • LY2784544Phase 21 trial

    Eli Lilly · Neoplasms, Hematologic

  • LY3457263Phase 21 trial

    Eli Lilly · Type 2 Diabetes

  • LY3537021Phase 21 trial

    Eli Lilly · Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions

  • LY3848575Phase 21 trial

    Eli Lilly · Neuropathic Pain, Distal Sensory Polyneuropathy

  • LY3871801Phase 21 trial

    Eli Lilly · Rheumatoid Arthritis

Recruiting Phase 3 trials

Largest first.

Marketed drugs (40)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.